Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc. Fundamental Analysis
Reneo Pharmaceuticals, Inc. (RPHM) shows weak financial fundamentals with a PE ratio of 65.95, profit margin of -50.87%, and ROE of 44.05%. The company generates $-0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -4707.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze RPHM's fundamental strength across five key dimensions:
Efficiency Score
ExcellentRPHM demonstrates superior asset utilization.
Valuation Score
ModerateRPHM shows balanced valuation metrics.
Growth Score
WeakRPHM faces weak or negative growth trends.
Financial Health Score
ExcellentRPHM maintains a strong and stable balance sheet.
Profitability Score
WeakRPHM struggles to sustain strong margins.
Key Financial Metrics
Is RPHM Expensive or Cheap?
P/E Ratio
RPHM trades at 65.95 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, RPHM's PEG of -0.11 indicates potential undervaluation.
Price to Book
The market values Reneo Pharmaceuticals, Inc. at 37.07 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 46.32 times EBITDA. This signals the market has high growth expectations.
How Well Does RPHM Make Money?
Net Profit Margin
For every $100 in sales, Reneo Pharmaceuticals, Inc. keeps $-50.87 as profit after all expenses.
Operating Margin
Core operations generate 83.40 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $44.05 in profit for every $100 of shareholder equity.
ROA
Reneo Pharmaceuticals, Inc. generates $51.27 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Reneo Pharmaceuticals, Inc. generates strong operating cash flow of $-1.08M, reflecting robust business health.
Free Cash Flow
Reneo Pharmaceuticals, Inc. generates strong free cash flow of $-1.09M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $-0.32 in free cash annually.
FCF Yield
RPHM converts -72.19% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
65.95
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.11
vs 25 benchmark
P/B Ratio
Price to book value ratio
37.07
vs 25 benchmark
P/S Ratio
Price to sales ratio
-82.89
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.01
vs 25 benchmark
Current Ratio
Current assets to current liabilities
11.45
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.44
vs 25 benchmark
ROA
Return on assets percentage
0.51
vs 25 benchmark
ROCE
Return on capital employed
-0.92
vs 25 benchmark
How RPHM Stacks Against Its Sector Peers
| Metric | RPHM Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 65.95 | 29.43 | Worse (Expensive) |
| ROE | 44.05% | 800.00% | Weak |
| Net Margin | -5087.33% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.01 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 11.45 | 4.64 | Strong Liquidity |
| ROA | 51.27% | -17936.00% (disorted) | Strong |
RPHM outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Reneo Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation